Company Description
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.
The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.
Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
| Country | United States |
| Founded | 1982 |
| IPO Date | Nov 18, 1996 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 134 |
| CEO | Jack Phillips |
Contact Details
Address: 3950 S. Country Club Road #470, Building 3-307 Tucson, Arizona 85714 United States | |
| Phone | 303-863-8088 |
| Website | acceleratediagnostics.com |
Stock Details
| Ticker Symbol | AXDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000727207 |
| CUSIP Number | 00430H102 |
| ISIN Number | US00430H2013 |
| Employer ID | 84-1072256 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Jack Phillips | Chief Executive Officer, President and Director |
| Lawrence Michael Mertz | Chief Technology Officer |
| David Patience | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
| Maya Gowri | Senior Vice President and Head of Operations |
| Laura Pierson | Investor Relations Officer |
| John Meduri | Chief Strategy Officer |
| Chris Thode | Senior Vice President of US Commercial |
| Rita Boukamel | Senior Vice President and Head of EMEA |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2024 | 8-K | Current Report |
| Apr 11, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 5, 2024 | 8-K | Current Report |
| Mar 5, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 25, 2024 | 8-K | Current Report |
| Jan 23, 2024 | 424B1 | Filing |
| Jan 19, 2024 | EFFECT | Notice of Effectiveness |
| Jan 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |